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S_manr A monoclonal antibody (MAb). 4D5. specifically recognising an extracellular epitope of the
c-ErbB-2 protein, inhibited the growth of human gastric cancer overexpressing c-ErbB-2 severe combined
immunodeficient (SCID) mice. This antibody also reduced the mass of established tumours xenografted into
SCID mice, whereas gastric cancer not expressing c-ErbB-2 exhibited no regression in response to 4D5
treatment. In addition, administration of 4D5 prevented colonisation of cancer cells and prolonged the
survival of host SCID mice inoculated i.v. with c-ErbB-2-overexpressing tumour cells. This is the first reported
study to show that treatment with a single antibody specific to c-ErbB-2 prolongs the survival of host SCID
mice bearing xenotransplanted tumours.
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The c-erbB-2 HER-2 proto-oncogene encodes a receptor-type
tyrosine kinase (Yarden and Ullrich, 1988) related to, but
different from, epidermal growth factor receptor (Coussens et
al., 1985; Yamamoto et al., 1986). The c-ErbB-2 protein is
expressed on the cell surface and consists of extracellular,
transmembrane and intracellular domains, the last possessing
kinase activity and autophosphorylation sites. Appreciable
amplification and/or overexpression of this gene has been
demonstrated in adenocarcinoma of the breast, ovary, lung
and stomach (King et al., 1985; Yokota et al., 1986; van de
Vijver et al., 1987; Slamon et al., 1989; Kern et al., 1990).
Amplification and/or overexpression was found in 8-40% of
gastric carcinoma patients and was linked to low survival
rates in the patients (Yokota et al.. 1988; Park et al., 1989;
Yomemura et al., 1991). c-ErbB-2 is weakly expressed in
normal tissues of adults (De Potter et al., 1989; Press et al.,
1990). From the above findings, the c-ErbB-2 protein is
thought to be a good target for antibody therapy of cancers
showing overexpression. Several series of MAbs recognising
the extracellular domain of the c-ErbB-2 protein have been
tested for their anti-human tumour effects, mainly in vitro,
and were found to produce inhibitory effects on cancer cell
lines overexpressing c-ErbB-2 (Drebin et al., 1985; Hudziak
et al., 1989; Hancock et al., 1991; Stancovski et al., 1991;
Tagliabue et al., 1991; Harwerth et al., 1992; Kasprzyk et al.,
1992). Only a few reports of the in vivo effects of MAbs on
tumours expressing the c-erbB-2 product have been pub-
lished. Stancovski et al., (1991) reported somewhat
conflicting results on the in vivo effects of these MAbs on
proliferation of murine fibroblasts transfected with the c-
erbB-2 gene. Only Kasprzyk et al.,. (1992) have demonstrated
regression of human tumours in nude mice by treatment with
two different anti-c-ErbB-2 MAbs, although each antibody
alone was not inhibitory. Whether or not the use of a single
MAb is effective in vivo for inducing human tumour regres-
sion and improving host survival and the mechanisms
involved in tumour regression in vivo remain unclear. A MAb
against the c-ErbB-2 protein, 4D5, which was generated by
Hudziak et al. (1989), has been reported to show cytostatic
effects in vitro on several human breast cancer cells (Fendly
et al., 1990) as well as reduction of pl85
2 phosphorylation
(Kumar et al., 1991). To study the in vivo effects of MAb
4D5 directed against the c-ErbB-2 protein on human tumour
regression and host survival, the extent of tumour mass
reduction and survival rate were detemined in treated vs
untreated mice bearing gastnc cancer overexpressing c-ErbB-
2.
Materials and methods
Animals
Balb/cA-nu mice were obtained from CLEA Japan Inc
(Tokyo, Japan). C.B-17-scid mice were a gift from Dr GC
Bosma (Fox Chase Cancer Center, Philadelphia, PA, USA)
and bred in our animal quarters. The mice were used at 6-8
weeks of age in accordance with the animal care guidelines of
the Central Institute for Experimental Animals (CIEA), in-
cluding animal anaesthesia procedures. We performed
periodic microbiological monitoring to confirm that the mice
were kept under specific pathogen-free conditions during the
experiment.
Cell lines and xenotransplanted tumour lines
The human breast cancer cell line SK-BR-3 was obtained
from the American Type Culture Collection (Rockville, MD,
USA) and maintained in Dulbecco's modified Eagle medium
(Sigma, St Louis, MO, USA) with 10% fetal bovine serum
(FBS, Flow Laboratories, McLean, VA, USA). Human gast-
ric carcinoma xenografts 4-1ST and St-15 were maintained at
the CIEA by serial inoculation in Balb/cA nude mice.
Anti-c-ErbB-2 antibody and control antibody for in vivo
anti-tumour assay
A murine MAb, 4D5, recognising the extracellular domain of
the c-ErbB-2 protein, was generated by Hudziak et al., (1989)
and supplied by Genentech. A class-matched MAb, HBs,
recognising the surface antigen of hepatitis B virus, was used
as the control.
Immunoblot analysis
Tumour samples stored in liquid nitrogen were lysed in lysis
buffer containing 20mM Hepes pH 7.2, 1% Tnrton X-100,
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10% glycerol, 1 mM EDTA, 1 mM sodium vanadate, 1 mM
phenylmethylsulphonyl fluoride and 1 tg ml-' aprotinin in
microtubes using a micropestle. The lysates were cleared by
centrifugation, and 5001tg of each lysate was
immunoprecipitated with 101 of 4D5 or HBs control MAb.
The protein was fractionated in 7.5% SDS- PAGE, transfer-
red to an Immobilon membrane (Millipore Japan, Tokyo),
probed with an anti-HER2/c-ErbB-2 antibody, CB11
(Novocastra Labs, UK) or an anti-phosphotyrosine
antibody, 5E3 (Fendly et al., 1990), and then treated with
horseradish peroxidase (HRP)-conjugated anti-mouse IgG.
Visualisation was performed using an ECL system (Amer-
sham Japan, Tokyo).
Northern blot analysis
Northern blot analysis was performed using the method
reported by Maniatis et al. (1989). Total cellular RNA
(20 tg) was fractionated in a 1.0% agarose gel containing 6%
formaldehyde and blotted onto a transfer membrane
(DuPont-NEN, Boston, MA, USA). The membrane was hyb-
ridised with a 3p- labeLld Xhol-KpnI fragment of HER2/c-
erbB-2 cDNA (Coussens et al., 1985), then rehybridised with
a chicken glyceraldehyde phosphate (GAPDH) cDNA probe,
and was analyzed using Fuji BAS2000 image analyser (Fuji
Film, Tokyo, Japan).
Preparation ofsingle-cell suspensions
Solid tumours in nude mice were resected, finely dispersed
using scissors, incubated in Hanks' balanced salt solution
containing 0.05% pronase (Boehringer Mannheim, Ger-
many), 0.02% collagenase type 1 (Sigma, St Louis, MO,
USA) and 0.02% DNAse I (Sigma) at 37C for 30 mi, and
passed finally through a nylon mesh to prepare single-cell
suspensions.
Inhibition oftumour take
Tumour cells were subcutaneously inoculated into the right
flank of severe combined immunodeficient (SCID) mice, fol-
lowed by i.v. injection of either 4D5 or HBs. Tumour mass
formation at the inoculation site was observed twice a week,
and tumour weight was measured on the day that the mice
were sacrificed.
Exponentialgrowth model
Effects on the tumours in the exponential growth phase were
examined by the method described previously (Inaba et al.,
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1988) using SCID mice instead of nude mice. In brief, a
tumour fragment was inoculated subcutaneously into the
right flank of SCID mice. Tumour size was measured twice a
week with calipers, and tumour volume was calculated
according to the formula tumour volume (mm3)= length
x (width)2/2. The mice were randomly divided into expen-
mental groups when each tumour had reached a palpable size
(100-300 mm3), and 4D5 or HBs MAb was then injected
intravenously into mice in each group. Statistical significnce
of differences was determined by the Mann-Whitney U-test.
Expermental lung metastasis model
One million 4-1ST cells were inoculated i.v. into the tail veins
of SCID mice, followed by i.v. injection of MAbs on days 1,
4 and 7 or 7, 10 and 13. Survival periods of mice were
observed for 180 days. When the animals showed severe
wasting and were apparently moribund owing to tumour
growth in the lung, the animals were not observed further
and the day of sacrifice was recorded according to the UKC-
CCR guidelines (Workman et al., 1988). Surviving animals
were sacrificed at the end of the experiment and sectioned for
microscopic examination of tumour foci. In a preliminary
experiment, mice inolculated with 1 x 106 4-1ST cells were
sacified on day 50 to confirm the presence of tumour foci
in the lung.
Resols
Expression ofc-ErbB-2product in hwnan gastric carcinoma
xenografts, 4-IST and St-15
To selet a suitable human tumour line as an in vivo model
for therapy using anti-c-ErbB-2 MAb, we first screened the
immunoreactivity with an anti-c-ErbB-2 polyclonal antibody
of 18 human gastric carcnomas xenotransplanted into nude
mice by immunoblotting (data not shown). Among these
tumours, the 4-1ST tumour lne derived from a poorly
differentiated adenocarcnoma revealed a clear band at a
moklular mass of 185 kDa, the reported molecular mass of
p185'2, whereas St-15 showed no reactive product
(Figure 1). 4-1ST also showed many bands with a lower
molcular mass than 185 kDa. We assume that these lower
bands were caused by reaction with the degraded c-ErbB-2
product, since the xenografted tumours contained necrotic
tissue in their centre. An anti-phosphotyrosine antibody, 5E3,
reacted with a 185 kDa protein immunoprecipitated from the
4-1ST tumour lysate with 4D5, suggesting that pl852
overexpressed in this tumour is phosphorylated (Figure 1).
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Figwe 1 Immunoblot analysis of c-ErbB-2 protein in human gastric tumour xenografts. Lysates from 4-1ST and St-15 human
gastric tumours were immunoprecipitated with 4D5 or the control MAb HBs. The immunoprecipitated proteins were fractionated
by SDS-PAGE, and transferred to a menbrane. The membrane was probed with anti-HER2/ErbB-2 antibody, CBII (left), or
anti-phosphotyrosine antibody, 5E3 (right), and then with HRP-conjugated anti-mouse antibody. Reactions were visualise using
the ECL system (Amnesham Japan). Arrowheads indicated pl85c2 and tyrosine-phosphorylated pl85`2. The small arrow
shows the Ig heavy chain used in immunoprecipitation.Northern blot analysis showed that the kvels of c-ErbB-2
gene expression in tumour 4-1ST but not St-15 were similar
to those in the SKBR-3 breast cancer cell line (Figure 2).
Inhibitory effects of4D5 on tumour growth in SCID mice
We first examined the transplantability of 4-1ST in SCID
mice. As shown in Table I (experiment 1), when more than
5 x 10' 4-1ST tumour cells were inoclated into SCID mice
subcutaneously, tumour nodules were formed in all mice
within 5 weeks. When 4D5 (12mgkg-') was injected 1, 4
and 7 days after inoculation of I x I05 4-1ST tumour clls,
the 4-1ST cells were eiminated from the mice, and no
tumour mass was formed even 90 days after inoclation
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Fum 2 pes of the c-erbB-2 gene in human gastric
tumour xaflgfts- Twenty mi gams of total cellular RNA
which obtained from 4-1ST, StI5 gstric tumour xenografts or
SKBR3 breast tumour cell line was fio and bloed onto
a membrane. The membane was bridised with 2Plabefled
c-erbB-2 or GAPDH cDNA for control of RNA integrity and
amount St-15 and 44ST: human gpstric tumour xenografts.
SKBR3: human breast tumour cell ine used as a postive control.
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(Table 1, e 2). Moreover, single adminitaton of
12mg kg-' or 6mg kg-' 4D5 on day 1 eliminated 2 x 105
4-1ST cells from all or 4/5 (80%) of the mice respecively,
whereas 2 x 105 4-1ST tumour cells showed take in the SCID
control mice (Table 1, experiment 3).
Effects of4D5 on exponentially growing tumors ui SCID mice
To examine whether injection of 4D5 caused regression of
establishd tumours, an experiment was performed after the
tumours had been allowed to grow measurably. When 4-1ST
tumour-bearing animals were treated with a single admini-
stration of 4D5 (36mg kg-'), tumour mass reduction was
obsved 10 days after adminisraton, although complete
regression was not observed (Figure 3a). Animals given inter-
mittent administration of4D5 (12 mg kg-I x 3) also showed
growth inhibition of 4-1ST. On the other hand, 4-1ST
tumours continued to grow when the animals were given the
control HBs antibody. St-15, expressing no
c-ErbB-2 protein, also continued to grow when the animals
were treated with 4D5. Intermittent treatment with
36mgkg ' x 3 4D5 caused a longer period oftumour reduc-
tion than single treatment for 4-1ST (Figure 3b). No loss of
body weight due to the antibody was observed in any treated
group.
Effects of4D5 on survival ofhosts with human tunours
Injection of tumour cls into the tail vein resulted in estab-
lishment oftumour foci in the hmgs (Figure 4a and b) and in
death of the mice within 80 days (Figure 4c). In conrast,
when the animals were treated with 4D5 (12mg kg- x 3) on
days 1, 4 and 7 or 7, 10 and 13, all survived without lung
metastass for as long as 180 days after tumour inoculation,
suggesing that treatment with 4D5 prevented tumour cell
colonisation and prolonged the survival of the host animals.
Several antibodies against the extracellular domain of the
c-erbB-2 gene product have been developed and tested for
their anti-tumour effects, mainly in vitro. Although a few
studies on their anti-tumour effects in vivo have also been
reported, it remains unclear whether or not an antibody
against the c-ErbB-2 protein can induce regression of human
cancers in vivo and prolong the survival of patients. In this
study, we demonstrated that an antibody against c-ErbB-2
protein reduced the growth of human tumours in mice and
Tae I Effects of4D5 on the growth of 44ST tumours inoculated subcutaneously into SCID
mice
Treatnet
Number of cells MAb dose schedule Take rate Tunor weight
( x 105) (mgkg-') Day 7 Day 21 Day 35 (g) mnean±si.
Expernent )
5 HBs 12 q3dX3b 4/5 5/5 5/5 NT
I HBs 12 q3dx3 2/5 5/5 5/5 NT
0.5 HBs 12 q3dx3 0/5 4/5 5/5 NT
Experiment 2
1 HBs 12 q3dx3 4/5 5/5 5/15 2.57 ± 0.59c
4D5 12 q3dx3 0/5 0/5 0/5 0"
Experimt 3
0.2 HBs 6 Sing 0/4 1/4 4/4 0.50 ± 0.40
2 Hbs 6 Single 3/3 3/3 3/3 2.60±0.07
2 4D5 6 Single 0/5 0/5 1/5 0.01
2 4D5 12 Single 0/5 0/5 0/5 NT
'Tumour nodules at the inocution sites wer grossly exa ed twice a week, and recorded as
the number ofmice with tumours o number of mice iwculated with 4-St_ b4D5 or
HBs MAb was injected i.v. on days 1, 4 and 7 after tumour inoculation. cMice were sari&ed 35
days after 44ST inocuation, and each tumour was weighed- No tumour was observed
micoscopicaly 13 weeks after tumour inoculation. c4D5 or HBs was injected i.v. on day 1 after
tumour inoculation. NT, not tested.Host swvilv by uikY-ErbB2 NAb
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rescued mice injected with human gastric cancer cells express-
ing c-ErbB-2.
Stancovski et al. (1991) generated a series of MAbs that
bound to the extracellular domain of c-ErbB-2 protein, and
found that some MAbs inhibited and the others enhanced
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the growth in vivo of murine fibroblasts transfected with the
c-erbB-2 gene. Although Kasprzyk et al. (1992) were the first
to report reducton of human tumour mass in nude mice by
treatment with two anti c-ErbB-2 MAbs, each of which
recognised a different epitope, the use of each antibody alone
did not inhibit tumour growth. In the present study, MAb
4D5 reduced the tumour size of the xenotransplanted human
gastric carcinoma 4-1ST in immunodeficient mice, although it
did not cause complete tumour regression. Hancock et al.
(1991) reported the synergistic effect of a MAb against c-
ErbB-2 plus cis-diamminedichloroplatinum.
The present study is the first to show that treatment with
an antibody (4D5) prolonged the survival time of host mice
injected with cancer cells overexpressing c-ErbBW2 without
any tumour mass in the lung. MAbs against c-erbB-2
generated by Stancovski et al. (1991) which showed anti-
tumour effects in vivo were found to stimulate slightly phos-
phorylation of tyrosine residues in the c-ErbB-2 receptor.
Stimulation of tyrosine phosphorylation by anti-c-ErbB-2
MAbs has also been reported elsewhere (Tagliabue et al.,
1991; Harwerth et al., 1992), although 4D5 has also been
shown to reduce p185112 phosphorylation (Kumar et al.,
1991). Hudziak et al. (1989) reported cytostatic effects of4D5
on tumour cells cultured in vitro, although inhibition of cell
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Figwe 3 Effects of 4D5 on exponentially growing tumours in
SCID mice. A tumour fragment was inoculated into the flank of
SCID mice. 4D5 treatment was started when the tumour volume
reached 100-300 mm3. Each group comprised six mice. (a) Mice
bearing c-ErbB-2-overexpressing 4-1ST tumours (solid symbols)
or c-ErbB-2-non-expressing St-15 tumours (open symbols) were
treated with a single injection of 36mgkg-' (triangles), three
injections of 12mgkg-' (once every 3 days, total 36mg kg-')
(circles) 4D5 or a single 36mg kg-' injection of control HBs
(squares). (b) Mice bearing 441ST were injected with q3d x3
36 mg kg-' 4D5 (circles) or the same dose of HBs control
antibody (squares). Bars indicate standard deviations.
C
40 50 60 70 80
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180
Fugue 4 Effects of 4D5 treatment on expenrmental lung col-
onisation and host survival. (a) Multiple tumour foci in a lung of
one of three mice sacrificed 50 days after intravenous inoculation
with I x 106 4-1ST cells (left) and an unremarkable lung of one
of the mice treated with 4D5 (right). (b) Histology of lung
resected from one of the HBs-treated control mice, showing
metastases ( x 20). (c) Nine mice in each group were treated with
4D5 (12mg kg-') on days 1, 4 and 7 (.) or days 7, 10 and 13
( - ) or with control HBs on days 1. 4 and 7( ) after
inoculation with I x 106 4-1ST cells.
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growth required continuous treatment with the antibody and
the cells regrew if the antibody was eliminated from the
culture medium. In the present study, treatment of micre with
4D5 reduced the mass of tumours growing exponentially in
mice by one half. In addition, treatment with the antibody
eliminated 2 x IO5 cells injected subcutaneously into the mice,
whereas injection of 2 x 14 cells resulted in the formation of
subcutaneous tumours when the mice were treated with a
control antibody. These findings suggest that 4D5 might act
on cancer cells in vivo not only through a direct receptor-like
function involving reduction of phosphorylation but also by
cell killing in concert with the host immune system, although
the exact mechanism responsible for the inhibition of tumour
growth by the antibody in mice is not completely clear. Lewis
et al. (1993) reported that mouse/human chimeric 4D5 and
humanised 4D5 showed an in vitro antibody-dependent
cytotoxic response to human tumour cell lines along with
human peripheral blood mononuclear cells. Larson et al.
(1988) also demonstrated macrophage-mediated cytotoxicity
in the suppression of human carcinoma growth in nude mice
by administration of MAbs directed against human colon
carcinoma.
Whatever the mechanism involved, our results showing
that MAb 4D5 was able to eliminate tumour cells from mice
bearing human gastnrc cancer and to rescue them from cancer
death suggest that the use of 4D5 as an adjuvant after
surgical resection might be effective for elimination of
minimal residual human gastric cancers overexpressing c-
ErbB-2 protein which respond poorly to currently available
systemic chemotherapies and are associated with poor prog-
nosis.
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